
Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.
Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Indication: Empagliflozin and linagliptin (Glyxambi)is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
Insight:
Sources:





